02575.HK_Providing professional financial news and data related to 02575.HK, committed to creating a comprehensive and efficient information access channel for users | NewTimeSpace

Xuanzhu Biology(02575.HK): First Patient Enrollment Completed in Phase III Clinical Trial of Anaprazole Sodium for New Indication

Tags：

Xuanzhu Biology 02575.HK

2026-06-21

Finance
ZCZL Industrial Technology (00564.HK): Application for A-share Convertible Bond Issuance Accepted by Shanghai Stock Exchange
Finance
OneRobotics (06600.HK): Proposes to Acquire Additional H-shares with Total Expense Not Exceeding HK$500 Million Pursuant to H-share Incentive Scheme
Finance
Xuanzhu Biology(02575.HK): First Patient Enrollment Completed in Phase III Clinical Trial of Anaprazole Sodium for New Indication
Finance
Easy Life Holdings (00223.HK): Appointment of Fung Chi Bun, Fung Man Shan and Han Wenli as Executive Directors
Finance
CloudMinds Technology (03310.HK): Stabilisation Period Concludes, Over-allotment Option Fully Exercised
Finance
Mabwell(02493.HK) Elects Dr. Gui Xun as Employee Representative Director
Finance
Ruixin International Group (00724.HK): Delisting to Take Effect from June 23
Finance
Ruihe Digital Intelligence (03680.HK): Supplementary Disclosure of Partnership Agreement Details, Clarifying AI Investment Strategy and Manager Qualifications
Finance
Far East Horizon (03360.HK): Update of US$4 Billion Medium-Term Note and Perpetual Securities Programme
Finance
PATEO Group (02889.HK): Executive Directors Propose to Increase Shareholdings with Maximum Total Value of HK$10 Million

Scan QR Code

Download App